EarlyDx is an epigenomics company advancing methylation-based liquid biopsy solutions to enable earlier detection, tissue-of-origin determination, and tumor-agnostic and variant-independent minimal residual disease (MRD) monitoring. Our proprietary MethylScan™ platform is a next-generation epigenomic platform that enables blood-based biomarker discovery, patient stratification, and clinical trial optimization.
DRTECH
DRTECH is a global provider of industry-leading diagnostic imaging solutions, established in 2000. We offer both indirect and direct flat panel detectors featuring distinctive, differentiating technologies that help our customers stay ahead in a competitive market. Our extensive product portfolio supports a wide range of applications including General Radiography, Mammography, Dental, Veterinary, Dynamic Imaging, and Industrial NDT. Our mission is to deliver innovative yet practical solutions that empower healthcare providers to elevate their standard of care.
Droplet Biosciences
Droplet Biosciences focused on the diagnostic and therapeutic utility of lymphatic fluid and is currently developing ultra-sensitive liquid-biopsy assays to detect molecular residual disease (MRD) across a range of cancers. Leveraging standard, powerful molecular diagnostic technologies and proprietary assay design, the company aims to provide clinicians with actionable information earlier than conventional methods, enabling adjuvant therapy decisions and improving patient outcomes.
DRGEM Corporation
DRGEM is a company specializing in X-ray technology. Since its establishment in September 2003, DRGEM has been dedicated exclusively to the field of X-ray imaging, offering a comprehensive range of solutions for general diagnostic X-ray systems. Through continuous research, development, and product innovation, we deliver exceptional X-ray equipment while fulfilling our responsibilities and commitments to our customers, ensuring their utmost satisfaction.
Dojindo Molecular Technologies, Inc.
With over 80 years of scientific heritage in Japan and more than 30 years of experience in the United States, Dojindo Laboratories and its U.S. subsidiary, Dojindo Molecular Technologies, support life-science research worldwide through innovative chemical tools and high-quality assay technologies. Dojindo Molecular Technologies specializes in the development and supply of unique fluorescence probes, cell-based assay kits, and biochemical reagents designed to enable precise analysis of cellular metabolism, redox biology, mitochondrial function, lysosomal dynamics, ferroptosis, and other cancer-relevant pathways. Our products are widely used in academic, pharmaceutical, and biotechnology research for both fundamental discovery and drug development.
DNAnexus
DNAnexus: Accelerating the Future of Human Genetics and Precision Medicine The advancement of human genetics hinges on our ability to navigate and interpret vast, complex datasets. As research pushes the boundaries of discovery, from single-gene disorders to population-scale genomics, the challenges of data management, analysis, and collaboration have grown exponentially. DNAnexus is at the forefront of this evolution, providing a secure, scalable, and collaborative cloud-based platform designed to meet the unique needs of the global life sciences community. We are on a journey to democratize how researchers and clinicians work with clinico-genomic data, transforming it into actionable discoveries that improve patient outcomes. Unifying Complex, Multi-Modal Data at Scale DNAnexus leads the way in the management and analysis of multi-omics data to accelerate breakthroughs in precision medicine. Our Precision Health Data Cloud empowers life science organizations to seamlessly integrate complex genomic, transcriptomic, proteomic, clinical, and real-world datasets. This unified approach provides a holistic view of human biology, enabling researchers to uncover novel insights into disease mechanisms, identify new therapeutic targets, and power the next wave of drug discovery and development. The platform is built to handle data at scale, providing the robust foundation necessary for everything from rare disease analysis to large-scale population health studies. Fostering Secure Collaboration and Innovation Scientific progress is a collaborative endeavor. The DNAnexus platform provides a secure and collaborative environment where data can be combined and analyzed, fostering innovation without compromising on security or compliance. We enable this through solutions like Trusted Research Environments (TREs), which provide regulatory-grade spaces for dynamic collaboration and efficient, compliant submissions. Our unwavering commitment to the highest security standards ensures that sensitive data, privacy, and intellectual property are protected, allowing your teams to focus on what matters most: accelerating scientific discovery. Harnessing AI-Powered Analytics for Actionable Insights Built upon this foundation of integrated data and security, DNAnexus offers robust, AI-driven analytics to unlock the full potential of your research. By leveraging advanced AI and machine learning tools, our platform helps you move beyond raw data to find meaningful patterns and actionable insights. This empowers your organization to speed the journey from research to patient impact, simplifying regulatory compliance and driving innovations that improve healthcare for all. Engage with DNAnexus at ASHG 2025 to explore how our pioneering data analysis and management solutions can empower your research and help translate genetic discoveries into the future of precision health.